SCHEMBL2486771

SCHEMBL2486771

CC(C)(C)C(=O)N1CCC[C@H]1C(=O)Nc1nc(-c2ccccc2)c(C(=O)c2ccccc2)s1

nearest known ligand 0.57

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA3 P0DMS8 9/20 0.57
SMN1; SMN2 Q16637 7/20 0.54
NPSR1 Q6W5P4 6/20 0.54
HTT P42858 4/20 0.54
MAPT P10636 3/20 0.54
LMNA P02545 3/20 0.54
ADORA1 P30542 8/20 0.54
ADORA2A P29274 4/20 0.54
KMT2A Q03164 3/20 0.53
MEN1 O00255 2/20 0.53
ALDH1A1 P00352 3/20 0.51
ADORA2B P29275 2/20 0.51
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
ALOX5 P09917 1/20 0.47
TDP1 Q9NUW8 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2317236 0.88 L3MBTL1 (0.56) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2490286 0.88 L3MBTL1 (0.56) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2485106 0.87 ADORA3 (0.57) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL27838817 0.85 NPSR1 (0.55) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2487161 0.83 ADORA3 (0.55) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2316301 0.77 ADORA3 (0.56) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2486141 0.76 LMNA (0.52) SMN1; SMN2HTTMAPTLMNAKMT2A
SCHEMBL2319346 0.74 ADORA3 (0.65) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL3185942 0.74 ADORA3 (0.70) ADORA3SMN1; SMN2NPSR1HTTMAPT
SCHEMBL2317625 0.73 ADORA3 (0.53) ADORA3SMN1; SMN2NPSR1HTTMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed
EP-2380631-A1 Heteroaryl derivatives as DGAT1 inhibitors Novartis AG (CH) 2011-10-26 EP disclosed